| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alamar Biosciences, Inc.
$27.77
-1.19 (-4.11%)
D 22Pipeline Score Diagnostics · Commercial
Market Cap
1.92 B
EPS
-
P/E Ratio
-
Value Trade
7.60 M
-9.16 %
Week
-24.06 %
1 Month
25.15 %
3 Month
26.23 %
6 Month
-10.21 %
5 Year
-10.21 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
340.00 K
52 Week Range
19.87 - 27.20
% held by Insiders
48.38 %
% held by Institutions
24.61 %
Enterprise Value
1.67 B
Total Shares
64.89 M
Short %
6.01 %
Float Shares
35.30 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alamar Biosciences, Inc.
1Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
TBD
T2Oral Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D22
Pipeline Score $94M
Pipeline ValueValuation Signal
2
Drugs Scored0.0x
rNPV / MCap Top 20%
Small Cap (rank 751 of 938)
Percentile RankAlamar Biosciences, Inc. faces pipeline headwinds (22/100), with $144M risk-adjusted pipeline value, led by ATTO-3712 in Normal Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATTO-3712 Small molecule | Normal Volunteers | Phase 1 | NCT07205081 | 10% | $72M | ACTIVE NOT_RECRUITING | 72 | AVERAGE | B (62) | Oct 1, 2026 | - | Aug 1, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALMR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALMR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALMRAlamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Alamar Biosciences, Inc. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company's management will engage in a fireside chat, which will be accessible via a live and archived webcast. Alamar is recognized for its advanced proteomics technology aimed at early disease detection.
Read more →ALMRAlamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Alamar Biosciences has launched the NULISAseq Immune 340 Panel, a comprehensive multiplexed immune profiling tool that measures approximately 340 immune-related proteins from a single sample. This panel enhances the understanding of the immune proteome, aiding research in cancer, cardiovascular, metabolic diseases, and autoimmune conditions. The technology promises to improve biomarker discovery and therapeutic development.
Read more →ALMRALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
ALZpath has expanded its strategic agreement with Alamar Biosciences to include clinical diagnostics for Alzheimer's disease. Alamar now holds commercial rights to use ALZpath's pTau217 antibody in blood-based diagnostic tests. This collaboration aims to enhance the accessibility of effective Alzheimer's testing for clinicians and patients, aligning with recent trends in blood biomarker adoption.
Read more →ALMRAlamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
Alamar Biosciences, Inc. will report its second quarter 2026 financial results on August 10, 2026, after market close. A conference call will follow at 1:30 p.m. PT, accessible via webcast. The company focuses on Precision Proteomics, utilizing advanced technology for protein detection.
Read more →ALMRAlamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
Alamar Biosciences has partnered with leading universities to launch a national initiative aimed at advancing blood-based biomarkers for Alzheimer's disease and related conditions. The project will analyze approximately 21,000 plasma samples using the NULISAseq Neuro 220 panel, creating a publicly accessible dataset linked to existing Alzheimer’s research. This initiative aims to enhance biomarker discovery and facilitate AI-driven research in neurodegenerative diseases.
Read more →ALMR▲ +7.3%on this newsshared move
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
Alamar Biosciences announced that its NULISA platform will be highlighted in over 140 presentations at the Alzheimer's Association International Conference (AAIC) 2026. This significant increase in data showcases the growing acceptance of multiplex protein profiling in Alzheimer's research. The company will also host a workshop demonstrating new assays that enhance detection and staging of Alzheimer's disease.
Read more →ALMRAlamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
Alamar Biosciences has launched the first commercial eMTBR-Tau immunoassay, which provides a non-invasive blood-based measurement of tau tangle pathology associated with Alzheimer's disease. This assay is part of the NULISAseq Neuro 220 panel and is designed to enhance disease staging and therapeutic response monitoring. Alamar will present data on this innovation at the AAIC 2026 workshop.
Read more →ALMR▼ -6%on this news
Targeting Inflammation by Pioglitazone and its R-Enantiomer Mitigates Pathological Myocardial Remodeling in Murine Hypertrophic Cardiomyopathy
The study by Cordula Wolf and colleagues demonstrates that pioglitazone and its R-enantiomer effectively target inflammation and metabolic issues in murine hypertrophic cardiomyopathy (HCM). R-pioglitazone significantly reduced interstitial fibrosis by over 95% and hypertrophy by 33%, while restoring mitochondrial function. These findings highlight R-pioglitazone's potential as a disease-modifying therapy for HCM.
Read more →ALMRDevelopment of a Novel Ultrasensitive Multiplex Proteomic Panel for Comprehensive Profiling of Immune and Inflammatory Biomarkers
The NULISAseq Immune 340 Panel has been developed to enhance the profiling of immune and inflammatory biomarkers. This innovative platform allows for the simultaneous quantification of over 340 proteins, demonstrating high sensitivity and specificity. It shows strong analytical robustness, with excellent precision and detectability in plasma and serum samples. The panel promises to advance diagnostic and therapeutic strategies for various diseases.
Read more →ALMRIn Navis Veritas – AAIC 2026 Alamar Event
The In Navis Veritas event, hosted by Alamar Biosciences, will take place on July 13 at the Cutty Sark in Greenwich, London. This gathering aims to facilitate meaningful discussions among leaders in neuro fluid biomarkers and advancements in Alzheimer's disease research. Attendees will have the chance to network and explore the future of neurodegenerative diagnostics.
Read more →ALMRCan Fingerstick Sampling Support Longitudinal Proteomics?
The article discusses the potential of dried blood spot sampling for proteomics, emphasizing its practicality for remote biological sample collection. It highlights the ability to ship samples at ambient temperature, which could facilitate access for participants in distant locations. The core question posed is whether these small-volume samples can reliably support multiplex protein measurement.
Read more →ALMRAlamar Biosciences Reports First Quarter 2026 Financial Results
Alamar Biosciences reported a record revenue of $26 million for Q1 2026, marking a 99% increase from the previous year. The company launched two new products aimed at neurodegenerative diseases and successfully completed an IPO, raising $220 million. However, operating and net losses also increased during this period.
Read more →ALMRAlamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
Alamar Biosciences, Inc. will participate in the BofA Securities 2026 Healthcare Conference in Las Vegas. The presentation is scheduled for May 12 at 3:40 p.m. PT. The company focuses on Precision Proteomics to improve disease detection through its proprietary technologies.
Read more →Competitive Position
How ALMR ranks across every disease it competes inCompetitive Position is a premium feature
See how ALMR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial